Kellie Tolin, MD
Psychiatry · Raleigh, NCNPI 1851373765
Payments from drug & device makers
Across 718 payments — averaging $42.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$20K
- AbbVie$2K
- Bausch Health US, LLC$964
- Otsuka America Pharmaceutical, Inc.$961
- Neurocrine Biosciences, Inc.$779
- Takeda Pharmaceuticals U.S.A., Inc.$705
- plus $6K from 25 others
What the payments were for
- Consulting fees$5052%
- Speaking & faculty fees$16,61054%
- Travel & lodging$1,8946%
- Food & beverage$11,58138%
- Education$100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 45 | $19,945 |
| AbbVie(2 entities) | 136 | $1,665 |
| Bausch Health US, LLC | 72 | $964 |
| Otsuka America Pharmaceutical, Inc. | 51 | $961 |
| Neurocrine Biosciences, Inc. | 45 | $779 |
| Takeda Pharmaceuticals U.S.A., Inc. | 41 | $705 |
| Lundbeck LLC | 45 | $620 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 33 | $612 |
| Teva Pharmaceuticals USA, Inc. | 36 | $565 |
| Idorsia Pharmaceuticals US Inc | 24 | $559 |
| Axsome Therapeutics, Inc. | 33 | $504 |
| Vanda Pharmaceuticals Inc. | 25 | $422 |
| Noven Therapeutics, LLC | 28 | $419 |
| Alkermes, Inc. | 18 | $390 |
| Corium, LLC | 11 | $234 |
| Tris Pharma Inc | 11 | $190 |
| Neos Therapeutics, LP | 8 | $139 |
| Sunovion Pharmaceuticals Inc. | 9 | $132 |
| Ironshore Pharmaceuticals Inc. | 7 | $119 |
| Shire North American Group Inc | 11 | $118 |
| Merck | 7 | $116 |
| E.r. Squibb & Sons, L.L.C. | 5 | $104 |
| Validus Pharmaceuticals LLC | 3 | $80 |
| Supernus Pharmaceuticals, Inc. | 3 | $79 |
| Jazz Pharmaceuticals Inc. | 2 | $35 |
| Adlon Therapeutics L.p. | 2 | $35 |
| Vertical Pharmaceuticals, LLC | 2 | $32 |
| Arbor Pharmaceuticals, Inc. | 2 | $28 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $19 |
| Almatica Pharma LLC | 1 | $15 |
| Alfasigma USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,600 in reported general payments places this provider in the 95th percentile of 1,108 psychiatry providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 11 | $170,138 |
| SpravatoEsketamine Hcl | 17 | $34,801 |
| RexultiBrexpiprazole | 12 | $27,249 |
| VraylarCariprazine Hcl | 12 | $16,887 |
| QuviviqDaridorexant Hcl | 21 | $9,545 |
| Bupropion XlBupropion Hcl | 61 | $1,682 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 35 | $1,610 |
| Ziprasidone Hcl | 25 | $1,266 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 33 | $1,134 |
| Duloxetine Hcl | 57 | $1,097 |
| Modafinil | 15 | $1,028 |
| Quetiapine Fumarate | 87 | $832 |
| Lamotrigine | 54 | $804 |
| Trazodone Hcl | 61 | $795 |
| Escitalopram Oxalate | 64 | $740 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $565 | $170,13811 claims |
| Johnson & JohnsonSpravato | $19,945 | $34,80117 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $961 | $27,24912 claims |
| AbbVieVraylar | $1,665 | $16,88712 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $559 | $9,54521 claims |
| Almatica Pharma LLCSertraline Hcl | $15 | $32150 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,108 psychiatry providers in North Carolina.
Other psychiatry in Raleigh
- Richard WeislerRaleigh$1.2M
- Robert MilletRaleigh$517K
- Ashwin PatkarRaleigh$170K
- Mona GuptaRaleigh$88K
- Celso LobaoRaleigh$28K
- Elizabeth CoxRaleigh$24K
- Craig ChepkeHuntersville$4.1M
- James BarkerHickory$4.1M
- Mark ReynoldsDurham$3.2M
- Oleg TcheremissineCharlotte$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.